In vitro metabolism of zolmitriptan in rat cytochromes induced with β-naphthoflavone and the interaction between six drugs and zolmitriptan

Chemico-Biological Interactions

Volumn 146, Issue 3, 2003, Pages 263-272

  Yu, Lu Shan ^a   Yao, Tong Wei ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cytochrome P450; Interaction; Metabolism; Microsomes; Zolmitriptan

Indexed keywords

BETA NAPHTHOFLAVONE; CIMETIDINE; CYTOCHROME P450 1A2; DIAZEPAM; DIPHENYLTRIAZOLE; DRUG METABOLITE; FLUVOXAMINE; MOCLOBEMIDE; N DEMETHYLASE; NORZOLMITRIPTAN; PROPRANOLOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME KINETICS; IN VITRO STUDY; LIVER MICROSOME; MALE; METABOLISM; METABOLITE; MICHAELIS CONSTANT; NONHUMAN; RAT;

EID: 0345293155     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2003.08.001     Document Type: Article

References (38)

1. Schoenen J., Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia. 17:1997;28-40.
2. Whale R., Bhagwagar Z., Cowen P.J. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology (Berl.). 145:1999;223-226.
3. Seaber E., On N., Phillips S., Churchus R.et al. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br. J. Clin. Pharmacol. 41:1996;141-147.
4. Seaber E., On N., Dixon R.M., Gibbens M.et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. J. Clin. Pharmacol. 43:1997;579-587.
5. Wild M.J., McKillop D., Butters C.J. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica. 29:1999;847-857.
6. Dantzg A.H., Shepard R.L., Law K.L.et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290:1999;854-862.
7. Nebbia C., Ceppa L., Dacasto M.et al. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily. Drug Metab. Dispos. 27:1999;1039-1044.
8. Sarver J.G., Bachmann K.A., Zhu D.et al. Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes. Drug Metab. Dispos. 26:1998;78-82.
9. Yamazaki H., Komatsu T., Takemoto K.et al. Rat cytochrome p450 1a and 3a enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes. Drug Metab. Dispos. 29:2001;794-797.
10. Soucek P. Cytochrome P450 destruction by quinines: comparison of effects in rats and human liver microsomes. Chem. Biol. Interact. 121:1999;223-236.
11. Easterbrook J., Fackett D., Li A.P. A comparison of aroclor1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin o-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylatin, s-mephenytoin 4′-hydroxylation chloroxazone 6-hydroxylation and testosterone 6-beta-hydroxylation. Chem. Biol. Interact. 134:2001;243-249.
12. Stiborova M., Martinek V., Rydlova H., Hodek P., Frei E. Sudan'I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P4501A1 and liver microsomes. Cancer Res. 62:2002;5678-5684.
13. Zhao X.J., Ishizaki T. The in vitro hepatic metabolism of quinine in mice. J. Pharmacol. Exp. Ther. 283:1997;1168-1176.
14. Kempf D.J., Marsh K.C., Kumar G. Pharmacokinetic enhancement of inhibitors of the human immune deficiency virus protease by coadministration with ritonavir, antimicrob-agents. Chemotherapy. 41:1997;654-660.
15. Nedelcheva V., Gut I., Soucek P., Frantik E. Cytochrome P450 catalyzed oxidation of mono chlorobenzene, 1, 2- and 1, 4-dichlorobenzene in rat, mouse and human liver microsomes. Chem. Biol. Interact. 115:1998;53-70.
16. Peck R.W., Seaber E.J., Dixon R.et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol. 44:1997;595-599.
17. Mei Q., Tang C., Assang C.et al. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J. Pharmacol. Exp. Ther. 291:1999;749-759.
18. Yang T.J., Shou M., Korzekwa K.R.et al. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem. Pharmacol. 55:1998;889-896.
19. Rolan P. Potential drug interaction with the novel antimigraine compound zolmitriptan (zomig, 311c90). Cephalalgia. 18:1997;21-27.
20. G.G. Gibson, P. Skett, Introduction Drug Metabolism, second ed., Blackie, London, 1994, p. 217.
21. Omura T., Sato R. The carbon monooxide-binding pigment of live microsomes. Part I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
22. L.S. Yu, T.W. Yao, S.J. Shen, et al., Determination of zolmitriptan and its metabolite in rat liver microsome by high-performance liquid chromatography with diode array detector, J. Chromatogr. B. (2003), in press.
23. I. Segal, Enzyme kinetics, Behavior and Analysis of rapid Equilibrium and Steady-State Enzyme Systems, Wiley, New York, 1975.
24. Dixon R., French S., Kemp J.et al. The metabolism of zolmitriptan. Effects of and inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin. Drug Invest. 15:1998;515-522.
25. R.B. Silverman, Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, CRC Press, Boca Raton, FL, 1988.
26. Chang T.K., Chen J., Lee W.B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther. 299:2001;874-882.
27. Roberts E.S., Alworth W.L., Hollenberg P.F. Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentrone. Arch. Biochem. Biophys. 354:1998;295-302.
28. Rodrigues A.D. Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem. Pharmacol. 48:1994;2147-2156.
29. Komatsu T., Yamazaki H., Shimada N.et al. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 28:2000;1457-1463.
30. Nielsen K.K., Flinois J.P., Beaune P.et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther. 277:1996;1659-1664.
31. Yao T.W., Hu Y.Z. RP-HPLC determination of diphentriazol in rat liver microsomal incubates and its application in in vitro metabolism. Acta Pharmaceut. Sinica. 37:2002;458-461.
32. McGinnity D.F., Parker A.J., Soars M.et al. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos. 28:2000;1327-1334.
33. Yun C.H., Hammons G.J., Jones G.et al. Modification of cytochrome P450 1A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl. Biochemistry. 31:1992;10556-10563.
34. Kunze K.L., Trager W.F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6:1993;649-656.
35. Racha J.K., Rettie A.E., Kunze K.L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry. 37:1998;7407-7419.
36. Masubuchi Y., Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydrazine in human liver microsomes. Chem. Res. Toxicol. 12:1999;1028-1032.
37. Carrillo J.A., Ramos S.I., Herraiz A.G.et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J. Clin. Psychopharmacol. 19:1999;494-499.
38. Carrillo J.A., Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin. Pharmacokinet. 39:2000;127-153.